Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer

Anti-Cancer Drugs

Volumn 18, Issue 7, 2007, Pages 835-837

  Gholam, Dany ^a,c   Chebib, Amale ^b   Hauteville, Dominique ^b   Bralet, Marie Pierre ^b   Jasmin, Claude ^b  

^a Centre Hospitalier Dracénie   (France)

^b HÔPITAL PAUL BROUSSE   (France)

^c Centre hospitalier de La Dracénie   (France)

Author keywords

Paclitaxel cetuximab; Skin metastases; Triple negative breast cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; MILTEFOSINE; NAVELBINE; PACLITAXEL; PROGESTERONE RECEPTOR;

ACNE; ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CASE REPORT; COMBINATION CHEMOTHERAPY; FATIGUE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MASTECTOMY; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PRIORITY JOURNAL; RASH; SKIN BIOPSY; SKIN METASTASIS; TREATMENT OUTCOME;

ACNEIFORM ERUPTIONS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PACLITAXEL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 34250873848     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e3280adc8e0     Document Type: Article

References (25)

1. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
3. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
4. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5568-5577.
5. Wen XZ, Li C, Wu Q-P. Potentiation of antitumor activity of PG-TXL with anti-EGFR monoclonal antibody C225 in MDA-MB-468 human breast cancer xenograft. Proc Am Assoc Cancer Res 2000; 41:323 (abstract 2052).
6. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocrine-related Cancer 2001; 8:3-9.
7. Raben D, Helfrich B, Chan D, Ciardiello F, Zhao L, Franklin W, et al. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 2005; 11:795-805.
8. Inoue K, Slaton J, Perrotte P, Davis DW, Bruns CJ, Hicklin DJ, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carinoma. Clin Cancer Res 2000; 6:4874-4884.
9. Singletary E, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20:3628-3636.
10. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: the value of histological grade in breast cancer. Histopathology 1991; 19:403-410.
11. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Sem Oncol 2006; 33:369-385.
12. DiGiovanna M, Stern D, Edgerton S, Whalen SG, Moore D II, Thor AD, et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005; 23:1152-1160.
13. Abd El-Rehim D, Pinder S, Paish C, Bell JA, Rampaul RS, Blamey RW, et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004; 91:1532-1542.
14. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y. Prognostic value of the combination of epidermal growth factor receptor and c-erbB-2 in breast cancer. Surgery 2003; 133:219-221.
15. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM. Therapeutic potential of chimeric and murine anti-EGFR antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993; 37:343-349.
16. Hamilton A, Hortobagyi G. Chemotherapy: what progress in the last 5 years? J Clin Oncol 2005; 23:1760-1775.
17. Baselga J, Seidman A, Rosen P, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Hunting) 1997; 11:43-44.
18. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol 2002; 13:1841-1851.
19. Sclabas GM, Fujioka S, Schmidt C, Fan Z, Evans DB, Chiao PJ. Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signalling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 2003; 7:37-43.
20. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998; 273:1568-1573.
21. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001; 344:783-792.
22. Tan AR, Yan X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, et al. Evaluation of biologic end-points and pharmacokinetics in patients with metastatic breast cancer after treatment with Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004; 22:3080-3090.
23. Modi S, D'andrea G, Norton L, Yao TJ, Caravelli J, Rosen PP, et al. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006; 7:270-277.
24. Siziopikou K, Ariga R, Proussaloglou KE, Gattuso P, Cobleigh M. The challenging estrogen receptor-negative/progesterone receptor-negative/HER-2- negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast J 2006; 12:360-362.
25. Livasy C, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19:264-271.